Mandate

Vinge advises Axcel in connection with the acquisition of Progrits, a leading software company in vertical software and information services

Progrits consists of ten businesses that develop specialised solutions within transport and logistics, vehicle digital solutions and integrated e-commerce. The B2B software company simplifies and automates customer information handling and workflows for approximately 5,000 Nordic and international customers.

The acquisition is subject to approval from applicable competition authority.

Vinge’s team consisted of Christina Kokko, Johanna Wiberg, Viktor Lennartsson, Nando Basic and Josef Groow (M&A), Mathilda Persson and Alva Skott (Commercial Agreements), August Ahlin (Banking and Financing), Madelene Andersson (Real Estate), Julia Löfqvist (Compliance), Tove Hallbäck (Employment), Lisa Hörnqvist (IT and GDPR), Arvid Axelryd and Felizia Wiker (Intellectual Property), Sebastian Örndahl, Victoria Fredén and Hampus Peterson (Merger filing) and Ellinore Boström Andersson (Project Assistant).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025